We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
Read MoreHide Full Article
Palisade Bio (PALI - Free Report) announced that it is in-licensing exclusive worldwide rights from private biotech, Giiant Pharma, to develop and commercialize gastrointestinal therapies targeting Inflammatory Bowel Disease (IBD). In response to this development, shares of PALI soared 109% on Sep 06.
The therapies targeting the IBD therapeutic area, which has multi-billion-dollar potential, will be developed by leveraging Giiant's proprietary targeted prodrug platform.
The licensed technologies include Giiant’s precision delivery technology platform and all of its promising pipeline candidates. Giiant’s lead candidate, GT-2108, is currently in pre-clinical development for patients suffering from moderate to severe ulcerative colitis. GT-2108 is a colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug that can be orally administered.
Palisade aims to submit an investigational new drug application to the FDA by the third quarter of 2024 to start clinical studies on GT-2108.
Palisade will also gain the rights to develop a pre-clinical candidate, GT-1908, which is an oral PDE4 compound targeting fibro stenotic Crohn's Disease. GT-1908 will be developed as a second program by PALI.
Under the terms of the licensing agreement, Palisade will partially contribute to the development costs until the first regulatory approval of Giiant’s pipeline candidates. Subsequently, PALI will take on full responsibility for the costs associated with the in-licensed candidate’s development, manufacturing and commercialization.
Shares of Palisade have plunged 87.3% year to date compared with the industry’s 12.0% decline.
Image Source: Zacks Investment Research
The collaboration will strengthen the company’s existing portfolio, which includes its lead candidate LB1148, being developed in a late-stage study for accelerating the time to return of postoperative bowel function.
LB1148 is a broad-spectrum serine protease inhibitor that aims to neutralize digestive enzymes and potentially reduce intestinal damage.
In the past 90 days, the Zacks Consensus Estimate forANI Pharmaceuticals’ earnings has gone up from $3.31 per share to $3.73 for 2023. The bottom-line estimate has increased from $4.32 to $4.35 for 2024 during the same time frame. Shares of the company have rallied 60.5% year to date.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 91.56%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to $2.77 for 2024 during the same time frame. Shares of the company have lost 8.1% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 62.9% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
Palisade Bio (PALI - Free Report) announced that it is in-licensing exclusive worldwide rights from private biotech, Giiant Pharma, to develop and commercialize gastrointestinal therapies targeting Inflammatory Bowel Disease (IBD). In response to this development, shares of PALI soared 109% on Sep 06.
The therapies targeting the IBD therapeutic area, which has multi-billion-dollar potential, will be developed by leveraging Giiant's proprietary targeted prodrug platform.
The licensed technologies include Giiant’s precision delivery technology platform and all of its promising pipeline candidates. Giiant’s lead candidate, GT-2108, is currently in pre-clinical development for patients suffering from moderate to severe ulcerative colitis. GT-2108 is a colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug that can be orally administered.
Palisade aims to submit an investigational new drug application to the FDA by the third quarter of 2024 to start clinical studies on GT-2108.
Palisade will also gain the rights to develop a pre-clinical candidate, GT-1908, which is an oral PDE4 compound targeting fibro stenotic Crohn's Disease. GT-1908 will be developed as a second program by PALI.
Under the terms of the licensing agreement, Palisade will partially contribute to the development costs until the first regulatory approval of Giiant’s pipeline candidates. Subsequently, PALI will take on full responsibility for the costs associated with the in-licensed candidate’s development, manufacturing and commercialization.
Shares of Palisade have plunged 87.3% year to date compared with the industry’s 12.0% decline.
Image Source: Zacks Investment Research
The collaboration will strengthen the company’s existing portfolio, which includes its lead candidate LB1148, being developed in a late-stage study for accelerating the time to return of postoperative bowel function.
LB1148 is a broad-spectrum serine protease inhibitor that aims to neutralize digestive enzymes and potentially reduce intestinal damage.
Palisade Bio, Inc. Price and Consensus
Palisade Bio, Inc. price-consensus-chart | Palisade Bio, Inc. Quote
Zacks Rank & Stocks to Consider
Palisade currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are ANI Pharmaceuticals (ANIP - Free Report) , Annovis Bio (ANVS - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate forANI Pharmaceuticals’ earnings has gone up from $3.31 per share to $3.73 for 2023. The bottom-line estimate has increased from $4.32 to $4.35 for 2024 during the same time frame. Shares of the company have rallied 60.5% year to date.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 91.56%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to $2.77 for 2024 during the same time frame. Shares of the company have lost 8.1% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 62.9% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.